NMUR1 specific inhibitory polypeptide and its application

By designing specific inhibitory peptides, imitating the N-terminal sequence of NMU polypeptides for mutation, blocking the activation of NMU receptors by NMU, solving the problem of poor efficacy of prostate cancer immunotherapy, and achieving effective inhibition of the NMUR1 axis and delaying tumor growth .

CN118580332BActive Publication Date: 2024-11-26RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411074333.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-26
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

The prior art has poor efficacy in immunotherapy for prostate cancer, lacking effective NMUR1 polypeptide antagonists, which cannot effectively block the NMUR1-mediated immunosuppressive process.

Method used

A NMUR1-specific inhibitory polypeptide was designed to mutate by mimicking the amino acid sites in the highly conserved sequence of the N-terminal NMU polypeptide to synthesize inhibitory polypeptides with stronger binding ability to block the activation process of NMU's NMUR1 receptor. Specific amino acid sequences include WLFRPYN, WLFHRTN, ELERPTN, etc., which are used to verify their inhibitory activity in vivo and in vitro.

Benefits of technology

It effectively blocked the activation of the NMU-NMUR1 axis, significantly improved the efficacy of immunotherapy in prostate cancer, delayed tumor progression, and verified its inhibitory properties in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118580332B_ABST
    Figure CN118580332B_ABST
Patent Text Reader

Abstract

The present invention discloses a NMUR1-specific inhibitory polypeptide; the NMUR1-specific inhibitory polypeptide is derived from a highly conserved sequence mutation at the N-terminus of the NMU polypeptide. The present invention also discloses an application of a NMUR1-specific inhibitory polypeptide in blocking the binding effect of NMU and NMUR1. Specifically, it relates to an application in blocking the stimulating effect of NMU on NMUR1 in intestinal lymphocytes and an application in blocking the stimulating effect of NMU on NMUR1 in bone marrow-derived mast cells. Also disclosed is an application of a NMUR1-specific inhibitory polypeptide in treating prostate cancer. The NMUR1-specific inhibitory polypeptide of the present invention has the effect of blocking the binding of NMU and NMUR1, and also has the effect of treating prostate cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of polypeptide construction, in particular to a NMUR1 specific inhibitory polypeptide and application thereof. Background Art

[0002] Prostate cancer is the most common cancer in men and the second leading cause of death among men worldwide. Due to the immunosuppressive nature of the prostate cancer tumor microenvironment, immunotherapy for prostate cancer is usually ineffective. Therefore, new and more effective treatment options for prostate cancer are urgently needed. NMUR1 has been reported to be expressed on the surface of immune cells such as ILC2 and mast cells, and plays an important role in mediating immunosuppression. However, there are currently no reported possible NMUR1 polypeptide antagonists. The present invention can block the NMUR1-mediated immunosuppressive process and provide a new treatment option for the development of prostate cancer treatment.

[0003] The article "Activation of neuromedin Utype 1 receptor inhibits L-type Ca2+ channel currents viaphosphatidylinositol 3-kinase-dependent protein kinase C epsilon pathway inmouse hippocampal neurons" published in Cellular Signalling in 2010 used the classic PKC antagonist CalphostinC (50 nmol / L) to pre-treat hippocampal neurons and eliminate the NMU response. However, according to its public content, it can be seen that CalphostinC does not necessarily inhibit NMUR1, but may only be related to its downstream signaling pathway. The binding affinity of CalphostinC and NMUR1 is not strong and the binding position is at the tail outside the hydrophobic cavity. Summary of the invention

[0004] The purpose of the present invention is to provide a NMUR1 specific inhibitory polypeptide and its application. The present invention synthesizes a specific inhibitory polypeptide for the NMU-NMUR1 ligand receptor binding process, which is used to block the activation process of NMU on the NMUR1 receptor, thereby changing the life activities dominated by this pathway in the body. The specific inhibitory polypeptide of the present invention helps to improve the current treatment status of prostate cancer.

[0005] The objective of the present invention is achieved through the following technical solutions:

[0006] <First aspect>

[0007] The present invention provides a NMUR1 specific inhibitory polypeptide, which is derived from a mutation of a highly conserved sequence at the N-terminus of a NMU polypeptide, and the amino acid sequence at the N-terminus of the NMU polypeptide is FLFRPRN (as shown in SEQ ID NO.1).

[0008] As one embodiment of the present invention, the amino acid sequence of the NMUR1-specific inhibitory polypeptide is WLFRPYN, WLFHRTN, ELERPTN, KLRHRTN, KLFRRYN or KLEHPYN.

[0009] Preferably, the amino acid sequence of the NMUR1-specific inhibitory polypeptide is WLFRPYN or ELERPTN.

[0010] As one embodiment of the present invention, the method for designing the NMUR1-specific inhibitory polypeptide comprises:

[0011] The N-terminus of the NMU polypeptide has a highly conserved sequence. The N-terminal amino acid sequence of the neuropeptide NMU is FLFRPRN (SEQ ID NO.1). NMU interacts with the hydrophobic cleft of NMUR1 through three hydrophobic amino acids Arg4, Arg6, and Asn7, thereby generating a strong binding affinity. This hydrophobic cavity is an ideal site for designing NMUR1 inhibition. By mutating the N-terminal amino acid sequence site of NMU and designing a series of peptide drugs that mimic the amino acid residues of NMU and conducting activity tests, inhibitory active peptides with stronger binding ability to the NMUR1 receptor can be selected.

[0012] <Second Aspect>

[0013] The present invention provides an application of the NMUR1 specific inhibitory polypeptide in preparing a drug for blocking the binding of NMU and NMUR1.

[0014] As one embodiment of the present invention, the NMUR1-specific inhibitory polypeptide is used in the preparation of a drug for blocking NMU stimulation of NMUR1 in intestinal lymphocytes.

[0015] As one embodiment of the present invention, the NMUR1-specific inhibitory polypeptide is used in the preparation of a drug for blocking NMU stimulation of NMUR1 in bone marrow-derived mast cells.

[0016] As one embodiment of the present invention, the method for verifying the polypeptide inhibitory activity of the NMUR1 specific inhibitory polypeptide is as follows:

[0017] This application uses both in vivo and in vitro experiments to double-verify the inhibitory activity of inhibitory peptides. In vitro experiments: Articles have reported that mast cells and ILC2 in intestinal lymphocytes express NMUR1 receptors, and NMU binding to them can promote the release of downstream cytokines by mast cells and ILC2. The experiment uses inhibitory peptides to specifically block the binding of NMU to the NMUR1 receptor on the surface of mast cells and ILC2 cells, and detects downstream cytokines to evaluate the inhibitory properties of the peptides. In vivo experiments: Inhibitory peptides are injected intratumorally into tumor-bearing mice for NMU-NMUR1 binding in the tumor, and tumor growth and immune infiltration are detected to evaluate the inhibitory activity of inhibitory peptides in vivo.

[0018] <Third Aspect>

[0019] The present invention provides an application of the NMUR1 specific inhibitory polypeptide in the preparation of tumor drugs.

[0020] As one embodiment of the present invention, the tumor comprises prostate cancer.

[0021] The role of the polypeptide in prostate cancer: prostate cancer highly expresses NMU, mast cells in prostate cancer tumors express NMUR1, and the binding of NMU-NMUR1 ligand receptors in tumors promotes the activation of mast cells, promotes immunosuppression in the tumor microenvironment, and further worsens prostate cancer. The inhibitory polypeptide synthesized in this application helps to block NMU-NMUR1-mediated tumor immunosuppression, and the combination of inhibitory polypeptide and ICB treatment can effectively improve the immunotherapy efficacy of prostate cancer.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) The present invention uses a method of mutating amino acid sites in the NMU conserved sequence to generate 6 possible inhibitory polypeptide sequences, and the 6 inhibitory polypeptides are used in in vitro and in vivo inhibition experiments to screen out polypeptides with inhibitory activity;

[0024] (2) The polypeptide inhibitors of the present invention have the ability to block the NMU-NMUR1 axis;

[0025] (3) The polypeptide inhibitor of the present invention is useful for treating prostate cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:

[0027] Figure 1 This is a diagram showing the blocking effect of the inhibitory polypeptide identified in Example 2 on the stimulation of NMU on NMUR1 in intestinal lymphocytes;

[0028] Figure 2 This is a diagram showing the blocking effect of the inhibitory polypeptide identified in Example 2 on the stimulation of NMU on NMUR1 in bone marrow-derived mast cells;

[0029] Figure 3 This is a diagram showing the growth inhibition effect of the inhibitory polypeptide on prostate tumors verified in mice in Example 3. DETAILED DESCRIPTION

[0030] The present invention is described in detail below in conjunction with specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, several variations and improvements may be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.

[0031] Example 1 Preparation of inhibitory polypeptides

[0032] The highly conserved peptide segment of NMU (FLFRPRN, as shown in SEQ ID NO.1) was mutated at multiple sites to generate 6 possible inhibitory polypeptide sequences for screening: WLFRPYN (as shown in SEQ ID NO.2), WLFHRTN (as shown in SEQ ID NO.4), ELERPTN (as shown in SEQ ID NO.3), KLRHRTN (as shown in SEQ ID NO.5), KLFRRYN (as shown in SEQ ID NO.6), KLEHPYN (as shown in SEQ ID NO.7). The polypeptides with stronger binding ability to NMUR1 receptor and inhibitory activity were selected; see the following examples for details.

[0033] Example 2 Screening and identification of NMUR1 inhibitory polypeptide inhibitory function

[0034] 2.1 Identification of its blocking effect on NMU stimulation of NMUR1 in intestinal lymphocytes

[0035] Separate the mouse intestinal lymph nodes, remove the mouse intestine, wash with clean HBSS for 5 minutes, repeat 3 times, cut the intestine into 1 cm2 pieces, add digestive enzymes (DMEM base solution, 2% FBS, 10mg / ml collagenase I, 10mg / ml collagenase IV, 1mg / ml Dnase I, 1mg / ml Dispase), shake at 100r / min, and digest for 1h. Neutralize the digestive enzymes with 10% FBS DMEM medium, centrifuge at 400g / min for 5min. Discard the supernatant and resuspend in medium.

[0036] Positive control group: Synthesized NMU peptide (synthesized by amino acid dehydration condensation method) was used to stimulate ILC2 immune cells expressing NMUR1 in intestinal lymphocytes. The transcription level of downstream type 2 cytokines was detected 4 hours later.

[0037] Experimental group: Synthetic NMU polypeptide was used to stimulate intestinal lymphocytes, and 100 ng / ml of the 6-segment NMUR1 specific inhibitory polypeptide synthesized in Example 1 was added. The transcription level of downstream type 2 cytokines was detected 4 hours later.

[0038] Control group: Synthetic NMU peptide was used to stimulate intestinal lymphocytes, and BSA with the same concentration as the inhibitory peptide in the experimental group was added. The transcription level of downstream type 2 cytokines was detected 4 hours later.

[0039] Observation indicators: Whether there is inhibition of type 2 cytokines at the transcriptional level in the experimental group compared with the positive control group. This is used to determine whether the specific inhibitory peptide blocks the stimulation of NMU on NMUR1 in intestinal lymphocytes.

[0040] The results are as follows Figure 1 As shown, the several groups of inhibitory peptides obtained in Example 1 have a wide range of inhibitory activation effects on the NMU-NMUR1 axis in ILC2.

[0041] 2.2 Identification of its blocking effect on NMU stimulation of NMUR1 in bone marrow-derived mast cells

[0042] Mouse bone marrow cells were isolated and mast cells were induced in vitro, which are called bone marrow-derived mast cells. BMMC induction medium: 1640 medium, 10% FBS, 10% BHK Condition Medium, IL3 30ng / ml, Glutamax 1× (ThermoFisher, 35050061), Sodium pyruvate 1mM. The induction time is 4-5 weeks.

[0043] Positive control group: bone marrow-derived mast cells were stimulated with synthetic NMU peptides, and downstream cytokine transcription levels were detected 4 hours later.

[0044] Experimental group: Synthetic NMU polypeptide was used to stimulate bone marrow-derived mast cells, and 100 ng / ml of the 6-segment NMUR1 specific inhibitory polypeptide synthesized in Example 1 was added. The transcription level of downstream cytokines was detected 4 hours later.

[0045] Control group: Synthetic NMU peptide was used to stimulate bone marrow-derived mast cells, and BSA at the same concentration as the inhibitory peptide in the experimental group was added. The transcription level of downstream cytokines was detected 4 hours later.

[0046] Observation indicators: Whether there is inhibition of cytokines at the transcriptional level in the experimental group compared with the positive control group. The activation of mast cells was detected to determine whether the specific inhibitory peptide blocked the stimulation of NMU on NMUR1 in bone marrow-derived mast cells.

[0047] The results are as follows Figure 2 As shown, two polypeptides with the sequences of WLFRPYN and ELERPTN have the best inhibitory effect on mast cell activation and have the effect of inhibiting the NMU-NMUR1 axis in mast cells.

[0048] Example 3 Therapeutic use of NMUR1 inhibitory polypeptide in prostate cancer

[0049] Prostate tumors were implanted subcutaneously in mice, and BSA was injected into the control group, while the specific inhibitory peptide WLFRPYN was injected into the experimental group. The tumor growth was observed to see whether it was delayed after the peptide was injected, in order to determine whether the specific inhibitory peptide blocked the stimulation of NMU on NMUR1 and delayed tumor progression.

[0050] The results are as follows Figure 3 As shown: Specific inhibitors can inhibit tumor progression. This proves that specific inhibitory peptides have the ability to block the stimulation of NMU on NMUR1 and have the ability to delay tumor progression in vivo.

[0051] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. A NMUR1 specific inhibitory polypeptide, characterized in that: The NMUR1 specific inhibitory polypeptide is derived from a mutation of a highly conserved sequence at the N-terminus of the NMU polypeptide, and its amino acid sequence is WLFRPYN, WLFHRTN, ELERPTN, KLRHRTN, KLFRRYN or KLEHPYN; the amino acid sequence at the N-terminus of the NMU polypeptide is FLFRPRN.

2. A use of the NMUR1 specific inhibitory polypeptide according to claim 1 in the preparation of a drug for treating prostate cancer, characterized in that: The amino acid sequence of the NMUR1 specific inhibitory polypeptide is WLFRPYN, ELERPTN or KLRHRTN.